{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T09:00:54Z","timestamp":1780131654118,"version":"3.54.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T00:00:00Z","timestamp":1768953600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T00:00:00Z","timestamp":1768953600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Microbiol Infect Dis"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s10096-026-05414-7","type":"journal-article","created":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T06:52:48Z","timestamp":1768978368000},"page":"1247-1256","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Reassessing the efficacy and safety of trimethoprim-sulfamethoxazole for Pneumocystis jirovecii pneumonia: a retrospective study"],"prefix":"10.1007","volume":"45","author":[{"given":"Yangmin","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danyang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fen","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Difei","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junjun","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujin","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haibin","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,21]]},"reference":[{"issue":"2","key":"5414_CR1","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1001\/jama.2023.9844","volume":"330","author":"S Zhou","year":"2023","unstructured":"Zhou S, Aitken SL (2023) Prophylaxis against Pneumocystis jirovecii pneumonia in adults. JAMA 330(2):182\u2013183. https:\/\/doi.org\/10.1001\/jama.2023.9844","journal-title":"JAMA"},{"issue":"7","key":"5414_CR2","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.3201\/eid2007.140087","volume":"20","author":"D Bitar","year":"2014","unstructured":"Bitar D, Lortholary O, Le Strat Y, Nicolau J, Coignard B, Tattevin P et al (2014) Population-based analysis of invasive fungal infections, France, 2001\u20132010. Emerg Infect Dis 20(7):1149\u20131155. https:\/\/doi.org\/10.3201\/eid2007.140087","journal-title":"Emerg Infect Dis"},{"issue":"4","key":"5414_CR3","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.jinf.2023.02.014","volume":"86","author":"K Pates","year":"2023","unstructured":"Pates K, Periselneris J, Russell MD, Mehra V, Schelenz S, Galloway JB (2023) Rising incidence of Pneumocystis pneumonia: a population-level descriptive ecological study in England. J Infect 86(4):385\u2013390. https:\/\/doi.org\/10.1016\/j.jinf.2023.02.014","journal-title":"J Infect"},{"issue":"8","key":"5414_CR4","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/j.cmi.2023.04.015","volume":"29","author":"L H\u00e4nsel","year":"2023","unstructured":"H\u00e4nsel L, Schumacher J, Denis B, Hamane S, Cornely OA, Koehler P (2023) How to diagnose and treat a patient without human immunodeficiency virus infection having Pneumocystis jirovecii pneumonia? Clin Microbiol Infect 29(8):1015\u20131023. https:\/\/doi.org\/10.1016\/j.cmi.2023.04.015","journal-title":"Clin Microbiol Infect"},{"key":"5414_CR5","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ijid.2016.03.018","volume":"46","author":"AL Bienvenu","year":"2016","unstructured":"Bienvenu AL, Traore K, Plekhanova I, Bouchrik M, Bossard C, Picot S (2016) Pneumocystis pneumonia suspected cases in 604 non-HIV and HIV patients. Int J Infect Dis 46:11\u201317. https:\/\/doi.org\/10.1016\/j.ijid.2016.03.018","journal-title":"Int J Infect Dis"},{"issue":"1","key":"5414_CR6","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s13613-024-01309-y","volume":"14","author":"T Kamel","year":"2024","unstructured":"Kamel T, Boulain T (2024) Pneumocystis pneumonia in French intensive care units in 2013\u20132019: mortality and immunocompromised conditions. Ann Intensive Care 14(1):80. https:\/\/doi.org\/10.1186\/s13613-024-01309-y","journal-title":"Ann Intensive Care"},{"issue":"9","key":"5414_CR7","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1093\/jac\/dkw158","volume":"71","author":"G Maschmeyer","year":"2016","unstructured":"Maschmeyer G, Helweg-Larsen J, Pagano L, Robin C, Cordonnier C, Schellongowski P (2016) ECIL guidelines for treatment of Pneumocystis jirovecii pneumonia in non-HIV-infected haematology patients. J Antimicrob Chemother 71(9):2405\u20132413. https:\/\/doi.org\/10.1093\/jac\/dkw158","journal-title":"J Antimicrob Chemother"},{"issue":"Rr\u20134","key":"5414_CR8","first-page":"1","volume":"58","author":"JE Kaplan","year":"2009","unstructured":"Kaplan JE, Benson C, Holmes KK, Brooks JT, Pau A, Masur H (2009) Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National institutes of Health, and the HIV medicine association of the infectious diseases society of America. MMWR Recomm Rep 58(Rr\u20134):1\u2013207 quiz CE1-4","journal-title":"MMWR Recomm Rep"},{"key":"5414_CR9","doi-asserted-by":"publisher","unstructured":"Thomas CF Jr., Limper AH (2004) Pneumocystis pneumonia. N Engl J Med 350(24):2487\u201398. https:\/\/doi.org\/10.1056\/NEJMra032588","DOI":"10.1056\/NEJMra032588"},{"issue":"6","key":"5414_CR10","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1016\/j.jmii.2017.07.007","volume":"51","author":"K Nakashima","year":"2018","unstructured":"Nakashima K, Aoshima M, Nakashita T, Hara M, Otsuki A, Noma S et al (2018) Low-dose trimethoprim-sulfamethoxazole treatment for pneumocystis pneumonia in non-human immunodeficiency virus-infected immunocompromised patients: a single-center retrospective observational cohort study. J Microbiol Immunol Infect 51(6):810\u201320. https:\/\/doi.org\/10.1016\/j.jmii.2017.07.007","journal-title":"J Microbiol Immunol Infect"},{"issue":"6","key":"5414_CR11","doi-asserted-by":"publisher","DOI":"10.1111\/tid.13737","volume":"23","author":"BJ Tritle","year":"2021","unstructured":"Tritle BJ, Hejazi AA, Timbrook TT (2021) The effectiveness and safety of low dose trimethoprim-sulfamethoxazole for the treatment of pneumocystis pneumonia: a systematic review and meta-analysis. Transpl Infect Dis 23(6):e13737. https:\/\/doi.org\/10.1111\/tid.13737","journal-title":"Transpl Infect Dis"},{"issue":"4","key":"5414_CR12","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1111\/1346-8138.15724","volume":"48","author":"H Kokubu","year":"2021","unstructured":"Kokubu H, Kato T, Nishikawa J, Tanaka T, Fujimoto N (2021) Adverse effects of trimethoprim-sulfamethoxazole for the prophylaxis of Pneumocystis pneumonia in dermatology. J Dermatol 48(4):542\u2013546. https:\/\/doi.org\/10.1111\/1346-8138.15724","journal-title":"J Dermatol"},{"key":"5414_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1422490","volume":"15","author":"HB Huang","year":"2024","unstructured":"Huang HB, Zhu YB, Yu DX (2024) Low-dose trimethoprim-sulfamethoxazole treatment for Pneumocystis pneumonia: a systematic review and meta-analysis. Front Pharmacol 15:1422490. https:\/\/doi.org\/10.3389\/fphar.2024.1422490","journal-title":"Front Pharmacol"},{"issue":"6","key":"5414_CR14","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.jcma.2016.01.007","volume":"79","author":"HM Chang","year":"2016","unstructured":"Chang HM, Tsai HC, Lee SS, Kunin C, Lin PC, Wann SR et al (2016) High daily doses of trimethoprim\/sulfamethoxazole are an independent risk factor for adverse reactions in patients with pneumocystis pneumonia and AIDS. J Chin Med Assoc 79(6):314\u20139. https:\/\/doi.org\/10.1016\/j.jcma.2016.01.007","journal-title":"J Chin Med Assoc"},{"key":"5414_CR15","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01173-17","author":"M Kosaka","year":"2017","unstructured":"Kosaka M, Ushiki A, Ikuyama Y, Hirai K, Matsuo A, Hachiya T et al (2017) A four-center retrospective study of the efficacy and toxicity of low-dose trimethoprim-sulfamethoxazole for the treatment of Pneumocystis pneumonia in patients without HIV infection. Antimicrob Agents Chemother. https:\/\/doi.org\/10.1128\/aac.01173-17","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"5414_CR16","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s15010-015-0851-1","volume":"44","author":"D Creemers-Schild","year":"2016","unstructured":"Creemers-Schild D, Kroon FP, Kuijper EJ, de Boer MG (2016) Treatment of Pneumocystis pneumonia with intermediate-dose and step-down to low-dose trimethoprim-sulfamethoxazole: lessons from an observational cohort study. Infection 44(3):291\u20139. https:\/\/doi.org\/10.1007\/s15010-015-0851-1","journal-title":"Infection"},{"issue":"5","key":"5414_CR17","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa112","volume":"7","author":"G Butler-Laporte","year":"2020","unstructured":"Butler-Laporte G, Smyth E, Amar-Zifkin A, Cheng MP, McDonald EG, Lee TC (2020) Low-Dose TMP-SMX in the treatment of Pneumocystis jirovecii pneumonia: a systematic review and meta-analysis. Open Forum Infect Dis 7(5):ofaa112. https:\/\/doi.org\/10.1093\/ofid\/ofaa112","journal-title":"Open Forum Infect Dis"},{"issue":"4","key":"5414_CR18","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.jiac.2018.11.014","volume":"25","author":"SI Ohmura","year":"2019","unstructured":"Ohmura SI, Naniwa T, Tamechika SY, Miyamoto T, Shichi D, Kazawa N et al (2019) Effectiveness and safety of lower dose sulfamethoxazole\/trimethoprim therapy for Pneumocystis jirovecii pneumonia in patients with systemic rheumatic diseases: a retrospective multicenter study. J Infect Chemother 25(4):253\u201361. https:\/\/doi.org\/10.1016\/j.jiac.2018.11.014","journal-title":"J Infect Chemother"},{"issue":"8","key":"5414_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.idnow.2024.104992","volume":"54","author":"J Taniguchi","year":"2024","unstructured":"Taniguchi J, Aso S, Jo T, Matsui H, Fushimi K, Yasunaga H (2024) Outcomes of low-dose trimethoprim-sulfamethoxazole treatment in patients with non-HIV pneumocystis pneumonia: a nationwide Japanese retrospective cohort study. Infect Dis Now 54(8):104992. https:\/\/doi.org\/10.1016\/j.idnow.2024.104992","journal-title":"Infect Dis Now"},{"issue":"7","key":"5414_CR20","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-053039","volume":"12","author":"ZN Sohani","year":"2022","unstructured":"Sohani ZN, Butler-Laporte G, Aw A, Belga S, Benedetti A, Carignan A et al (2022) Low-dose trimethoprim-sulfamethoxazole for the treatment of Pneumocystis jirovecii pneumonia (LOW-TMP): protocol for a phase III randomised, placebo-controlled, dose-comparison trial. BMJ Open 12(7):e053039. https:\/\/doi.org\/10.1136\/bmjopen-2021-053039","journal-title":"BMJ Open"},{"issue":"2","key":"5414_CR21","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1097\/qco.0000000000001002","volume":"37","author":"T Saadatzadeh","year":"2024","unstructured":"Saadatzadeh T, Angarone M, Stosor V (2024) Pneumocystis jirovecii in solid organ transplant recipients: updates in epidemiology, diagnosis, treatment, and prevention. Curr Opin Infect Dis 37(2):121\u2013128. https:\/\/doi.org\/10.1097\/qco.0000000000001002","journal-title":"Curr Opin Infect Dis"},{"issue":"4","key":"5414_CR22","doi-asserted-by":"publisher","first-page":"c179","DOI":"10.1159\/000339789","volume":"120","author":"A Khwaja","year":"2012","unstructured":"Khwaja A (2012) KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract 120(4):c179\u2013c184. https:\/\/doi.org\/10.1159\/000339789","journal-title":"Nephron Clin Pract"},{"issue":"1","key":"5414_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-019-0105-0","volume":"5","author":"RJ Andrade","year":"2019","unstructured":"Andrade RJ, Chalasani N, Bj\u00f6rnsson ES, Suzuki A, Kullak-Ublick GA, Watkins PB et al (2019) Drug-induced liver injury. Nat Rev Dis Primers 5(1):58. https:\/\/doi.org\/10.1038\/s41572-019-0105-0","journal-title":"Nat Rev Dis Primers"},{"issue":"49","key":"5414_CR24","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.220499","volume":"194","author":"S Mithoowani","year":"2022","unstructured":"Mithoowani S, Cameron L, Crowther MA (2022) Neutropenia. Can Med Assoc J 194(49):E1689. https:\/\/doi.org\/10.1503\/cmaj.220499","journal-title":"Can Med Assoc J"},{"issue":"4","key":"5414_CR25","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1378\/chest.13-0121","volume":"144","author":"DR Williamson","year":"2013","unstructured":"Williamson DR, Albert M, Heels-Ansdell D, Arnold DM, Lauzier F, Zarychanski R et al (2013) Thrombocytopenia in critically ill patients receiving thromboprophylaxis: frequency, risk factors, and outcomes. Chest 144(4):1207\u201315. https:\/\/doi.org\/10.1378\/chest.13-0121","journal-title":"Chest"},{"key":"5414_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/2110-5820-4-13","volume":"4","author":"GR Brown","year":"2014","unstructured":"Brown GR (2014) Cotrimoxazole - optimal dosing in the critically ill. Ann Intensive Care 4:13. https:\/\/doi.org\/10.1186\/2110-5820-4-13","journal-title":"Ann Intensive Care"},{"issue":"12","key":"5414_CR27","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1016\/j.cmi.2020.02.021","volume":"26","author":"J Rajput","year":"2020","unstructured":"Rajput J, Moore LSP, Mughal N, Hughes S (2020) Evaluating the risk of hyperkalaemia and acute kidney injury with cotrimoxazole: a retrospective observational study. Clin Microbiol Infect 26(12):1651\u20131657. https:\/\/doi.org\/10.1016\/j.cmi.2020.02.021","journal-title":"Clin Microbiol Infect"},{"issue":"5","key":"5414_CR28","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1093\/jac\/dks030","volume":"67","author":"TN Fraser","year":"2012","unstructured":"Fraser TN, Avellaneda AA, Graviss EA, Musher DM (2012) Acute kidney injury associated with trimethoprim\/sulfamethoxazole. J Antimicrob Chemother 67(5):1271\u20131277. https:\/\/doi.org\/10.1093\/jac\/dks030","journal-title":"J Antimicrob Chemother"},{"issue":"8","key":"5414_CR29","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.21037\/tp-21-600","volume":"11","author":"M Ju","year":"2022","unstructured":"Ju M, Zheng M, Yuan J, Lin D, Qian Y (2022) Prevalence and risk factors of trimethoprim\/sulfamethoxazole-related acute kidney injury in pediatric patients: an observational study from a public database. Transl Pediatr 11(8):1285\u20131291. https:\/\/doi.org\/10.21037\/tp-21-600","journal-title":"Transl Pediatr"},{"issue":"1","key":"5414_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s40780-022-00251-0","volume":"8","author":"Y Shimizu","year":"2022","unstructured":"Shimizu Y, Hirai T, Ogawa Y, Yamada C, Kobayashi E (2022) Characteristics of risk factors for acute kidney injury among inpatients administered sulfamethoxazole\/trimethoprim: a retrospective observational study. J Pharm Health Care Sci 8(1):20. https:\/\/doi.org\/10.1186\/s40780-022-00251-0","journal-title":"J Pharm Health Care Sci"},{"issue":"9","key":"5414_CR31","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1111\/jcpt.13679","volume":"47","author":"S Yokoyama","year":"2022","unstructured":"Yokoyama S, Nakagawa J, Aiuchi N, Seito T, Niioka T (2022) Impact of trimethoprim on serum creatinine, sodium, and potassium concentrations in patients taking trimethoprim-sulfamethoxazole without changes in glomerular filtration rate. J Clin Pharm Ther 47(9):1409\u20131417. https:\/\/doi.org\/10.1111\/jcpt.13679","journal-title":"J Clin Pharm Ther"},{"issue":"6","key":"5414_CR32","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1093\/ndt\/gfac282","volume":"38","author":"YJ Hwang","year":"2023","unstructured":"Hwang YJ, Muanda FT, McArthur E, Weir MA, Sontrop JM, Lam NN et al (2023) Trimethoprim-sulfamethoxazole and the risk of a hospital encounter with hyperkalemia: a matched population-based cohort study. Nephrol Dial Transplant 38(6):1459\u201368. https:\/\/doi.org\/10.1093\/ndt\/gfac282","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"5414_CR33","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1038\/ki.1996.193","volume":"49","author":"S Eiam-Ong","year":"1996","unstructured":"Eiam-Ong S, Kurtzman NA, Sabatini S (1996) Studies on the mechanism of trimethoprim-induced hyperkalemia. Kidney Int 49(5):1372\u20131378. https:\/\/doi.org\/10.1038\/ki.1996.193","journal-title":"Kidney Int"},{"issue":"12","key":"5414_CR34","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1177\/1060028013509973","volume":"47","author":"CA Gentry","year":"2013","unstructured":"Gentry CA, Nguyen AT (2013) An evaluation of hyperkalemia and serum creatinine elevation associated with different dosage levels of outpatient trimethoprim-sulfamethoxazole with and without concomitant medications. Ann Pharmacother 47(12):1618\u20131626. https:\/\/doi.org\/10.1177\/1060028013509973","journal-title":"Ann Pharmacother"},{"issue":"12","key":"5414_CR35","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1001\/archinternmed.2010.142","volume":"170","author":"T Antoniou","year":"2010","unstructured":"Antoniou T, Gomes T, Juurlink DN, Loutfy MR, Glazier RH, Mamdani MM (2010) Trimethoprim-sulfamethoxazole-induced hyperkalemia in patients receiving inhibitors of the renin-angiotensin system: a population-based study. Arch Intern Med 170(12):1045\u20131049. https:\/\/doi.org\/10.1001\/archinternmed.2010.142","journal-title":"Arch Intern Med"},{"key":"5414_CR36","doi-asserted-by":"publisher","first-page":"d5228","DOI":"10.1136\/bmj.d5228","volume":"343","author":"T Antoniou","year":"2011","unstructured":"Antoniou T, Gomes T, Mamdani MM, Yao Z, Hellings C, Garg AX et al (2011) Trimethoprim-sulfamethoxazole induced hyperkalaemia in elderly patients receiving spironolactone: nested case-control study. BMJ 343:d5228. https:\/\/doi.org\/10.1136\/bmj.d5228","journal-title":"BMJ"},{"issue":"1","key":"5414_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-019-3944-0","volume":"19","author":"GVR Prasad","year":"2019","unstructured":"Prasad GVR, Beckley J, Mathur M, Gunasekaran M, Nash MM, Rapi L et al (2019) Safety and efficacy of prophylaxis for Pneumocystis jirovecii pneumonia involving trimethoprim-sulfamethoxazole dose reduction in kidney transplantation. BMC Infect Dis 19(1):311. https:\/\/doi.org\/10.1186\/s12879-019-3944-0","journal-title":"BMC Infect Dis"}],"container-title":["European Journal of Clinical Microbiology & Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-026-05414-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10096-026-05414-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-026-05414-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T08:04:01Z","timestamp":1780128241000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10096-026-05414-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,21]]},"references-count":37,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["5414"],"URL":"https:\/\/doi.org\/10.1007\/s10096-026-05414-7","relation":{},"ISSN":["0934-9723","1435-4373"],"issn-type":[{"value":"0934-9723","type":"print"},{"value":"1435-4373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,21]]},"assertion":[{"value":"29 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of the Second Affiliated Hospital, School of Medicine, Zhejiang University (No. 2024\u2009\u2212\u20091253). Informed consent was waived by this committee due to the retrospective nature of the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}